Union européenne -
estonien -
EMA (European Medicines Agency)
abecma
bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastilised ained - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
Estonie -
estonien -
Ravimiamet
topimec f süstelahus
chanelle pharmaceuticals manufacturing limited - ivermektiin+klorsuloon - süstelahus - 10mg+100mg 1ml 500ml 1tk; 10mg+100mg 1ml 250ml 1tk
Estonie -
estonien -
Adama
sultan® super
adama - suspensioonikontsentraat - kvinmerak + metasakloor - herbitsiidid
Union européenne -
estonien -
EMA (European Medicines Agency)
camcevi
accord healthcare s.l.u. - leuprorelin mesilate - eesnäärmevähk - endokriinset ravi - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
Union européenne -
estonien -
EMA (European Medicines Agency)
stimufend
fresenius kabi deutschland gmbh - pegfilgrastim - neutropeenia - immunostimulants, , mesilaspere stimuleerivaid faktoreid - neutropeenia ja febriilse neutropeenia esinemissageduse vähendamine ravitud tsütotoksilise kemoteraapia pahaloomulise kasvaja (välja arvatud krooniline müeloidne leukeemia ja müelodüsplastilised sündroomid).
Union européenne -
estonien -
EMA (European Medicines Agency)
litfulo
pfizer europe ma eeig - ritlecitinib tosilate - alopecia areata - immunosupressandid - litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.
